Vanguard Group Inc. Purchases 519,897 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Vanguard Group Inc. raised its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 7.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,606,242 shares of the company's stock after buying an additional 519,897 shares during the quarter. Vanguard Group Inc. owned approximately 5.13% of Xeris Biopharma worth $16,810,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its position in Xeris Biopharma by 66.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 26,516 shares of the company's stock worth $59,000 after acquiring an additional 10,543 shares during the period. SG Americas Securities LLC grew its position in Xeris Biopharma by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 33,777 shares of the company's stock valued at $79,000 after buying an additional 15,414 shares during the last quarter. Quarry LP acquired a new position in Xeris Biopharma in the 4th quarter valued at $47,000. Diversified Trust Co raised its position in Xeris Biopharma by 12.9% during the 1st quarter. Diversified Trust Co now owns 175,741 shares of the company's stock worth $388,000 after buying an additional 20,091 shares during the last quarter. Finally, Eagle Asset Management Inc. acquired a new stake in shares of Xeris Biopharma in the 4th quarter worth $48,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on XERS shares. HC Wainwright reiterated a "buy" rating and set a $6.00 price target on shares of Xeris Biopharma in a research note on Friday, May 31st. Piper Sandler reiterated an "overweight" rating and set a $3.00 target price (down previously from $4.00) on shares of Xeris Biopharma in a research report on Friday, May 10th.

Xeris Biopharma Stock Up 12.9 %

Shares of NASDAQ XERS traded up $0.29 during midday trading on Tuesday, hitting $2.54. The stock had a trading volume of 2,639,712 shares, compared to its average volume of 1,776,864. The company has a fifty day moving average price of $2.29 and a 200 day moving average price of $2.28. The company has a market capitalization of $376.57 million, a price-to-earnings ratio of -5.13 and a beta of 2.72. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.46 and a 1-year high of $3.26.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The business had revenue of $48.07 million during the quarter, compared to analyst estimates of $46.80 million. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. During the same period last year, the business earned ($0.14) EPS. On average, research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.39 EPS for the current year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.